dTMS for Subjective Cognitive Decline
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-70
SponsorRotman Research Institute at Baycrest
About this trial
Deep transcranial magnetic stimulation (dTMS) is a brain stimulation technique that involves generating a brief magnetic field in a coil that is placed on the scalp. The magnetic field passes through the skull and induces a weak electrical current in the brain that briefly activates neural circuits at the stimulation site. The Brainsway dTMS H7-Coil is able to target an area of the brain that has been shown in studies to be linked to greater resilience to cognitive decline. In this study, the investigators will combine dTMS with cognitive training in older adults with subjective cognitive decline (SCD) and examine the effect of this treatment on memory, other cognitive abilities, and mood. In addition, the investigators will examine the combined effects of dTMS and cognitive training on brain activity as measured using electroencephalography (EEG).
Approximately 30 older adults from ages 55 to 70 with SCD and a positive family history of Alzheimer's disease will be enrolled in this study.
Eligibility criteria
Qualifiers
have a family history of late onset sporadic Alzheimer's disease (AD) as defined by having a first degree relative, living or deceased, with a probable or confirmed diagnosis of AD
have subjective memory decline and concern about memory changes
score 26 or higher on the Montreal Cognitive Assessment (MoCA)
are willing to provide informed consent
Disqualifiers
have a metal plate in their head, except in the mouth (such as an ear implant, implanted brain stimulators, aneurysm clips)
have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures
have a cardiac pacemaker
have an implanted medication pump
Trial design
Treatments tested in this trial
- Active Brainsway H7-Coil Deep TMS System
- Sham Brainsway H7-Coil Deep TMS System
- Cognitive Training
Treatment groups
30 Participants
are divided into 2 treatment groupsSponsors and collaborators
Rotman Research Institute at Baycrest
Lead sponsor
Brainsway
Collaborator
Centre for Addiction and Mental Health
Collaborator
Source ClinicalTrials.gov